Brief: Revolution Medicines Says Daraxonrasib Shows Improvement In Survival In Late-Stage Pancreatic Cancer Study
13/04/2026 13:00
April 13 (Reuters) - Revolution Medicines Inc RVMD.O: REVOLUTION MEDICINES: PHASE 3 RASOLUTE 302 TRIAL MET ALL PRIMARY & KEY SECONDARY ENDPOINTS REVOLUTION MEDICINES: DARAXONRASIB SHOWS OVERALL SURVIVAL BENEFIT IN PHASE 3 RASOLUTE 302 TRIAL IN PATIENTS WITH METASTATIC PANCREATIC CANCER REVOLUTION MEDICINES: DARAXONRASIB GENERALLY WELL TOLERATED, WITH MANAGEABLE SAFETY PROFILE IN PATIENTS WITH PDAC & WITH NO NEW SAFETY SIGNALS REVOLUTION MEDICINES: DARAXONRASIB DEMONSTRATED MEDIAN OVERALL SURVIVAL OF 13.2 MONTHS VERSUS 6.7 MONTHS FOR CHEMOTHERAPY Further company coverage: RVMD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revolution Medicines
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns